Patent · US Active

Nanocapsule delivery system for ribonucleoproteins

US11013695B2 · kind B2 · utility

0Cited by
1References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 27, 2018
Grant dateMay 25, 2021
Priority date
Expiry dateNov 26, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2800/80
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are nanocapsules comprising a single ribonucleoprotein (RNP) complex as a core and an biodegradable crosslinked polymer shell that encapsulates the core, wherein the RNP complex comprises a Cas9 polypeptide and a guide RNA, and the biodegradable crosslinked polymer shell comprises polymerized monomers of imidazolyl acryloyl monomers, bisacryloyl disulfide monomers (a biodegradable cross-linker), optionally PEG acryloyl monomers, and either cationic acryloyl monomers, anionic acryloyl monomers, or both cationic and anionic acryloyl monomers (optionally in combination with non-ionic acryloyl monomers) as defined herein. Also provided are methods of making the nanocapsules, kits containing the nanocapsules and methods of delivering the encapsulated RNP to cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.